Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
5(31%)
Results Posted
0%(0 trials)
Terminated
1(6%)

Phase Distribution

Ph not_applicable
5
31%
Ph phase_2
4
25%
Ph phase_3
5
31%

Phase Distribution

0

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution14 total trials
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
5(35.7%)
N/ANon-phased studies
5(35.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

5

trials recruiting

Total Trials

16

all time

Status Distribution
Active(6)
Completed(5)
Terminated(1)
Other(4)

Detailed Status

Completed5
unknown4
Recruiting4
Not yet recruiting1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
5
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (28.6%)
Phase 35 (35.7%)
N/A5 (35.7%)

Trials by Status

unknown425%
completed531%
recruiting425%
not_yet_recruiting16%
active_not_recruiting16%
terminated16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT07236320Not Applicable

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

Completed
NCT04378023

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Recruiting
NCT01815853Phase 3

Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

Completed
NCT06775652Phase 3

Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC

Completed
NCT06762158Not Applicable

NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC

Active Not Recruiting
NCT05496491Not Applicable

Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial

Recruiting
NCT06097416Phase 3

Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer

Not Yet Recruiting
NCT04973306Phase 2

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Recruiting
NCT04807673Phase 3

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Recruiting
NCT03504449Not Applicable

Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial

Unknown
NCT03001596Not Applicable

Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC

Completed
NCT04027543

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)

Completed
NCT01926483Phase 2

Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection

Unknown
NCT01463501Phase 2

Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer

Unknown
NCT01187290Phase 2

Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases

Unknown
NCT00559351Phase 3

RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus

Terminated

All 16 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
16